Crossmark

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1038/s41416-022-01978-1

Published Online: 2022-09-29

Published Print: 2022-11-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zulato, Elisabetta

Del Bianco, Paola

Nardo, Giorgia

Attili, Ilaria

Pavan, Alberto

Boscolo Bragadin, Andrea

Marra, Ludovica

Pasello, Giulia

Fassan, Matteo

Calabrese, Fiorella

Guarneri, Valentina

Conte, Pier Franco

Indraccolo, Stefano https://orcid.org/0000-0002-4810-7136
Bonanno, Laura https://orcid.org/0000-0001-5218-4970
Funding

Funding for this research was provided by:

5x1000 IOV intramural grant
License Information

Text and Data Mining valid from 2022-09-29

Version of Record valid from 2022-09-29
More Information

Article History

Received: 24 February 2022

Revised: 24 August 2022

Accepted: 31 August 2022

First Online: 29 September 2022

Competing interests

: The authors declare no competing interests.

: The ethics committee of Istituto Oncologico Veneto evaluated and approved the study design and informed consent (2016/82, 12/12/2016). Written informed consent was obtained from all patients before study entry. The study was conducted in accordance with the precepts of the Helsinki declaration.

: The property of data belongs to the sponsor, IOV, and the authors have the right to publish the data.

Document is current

Any future updates will be listed below